Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Receivables (2016 - 2025)

International Stem Cell (ISCO) has disclosed Receivables for 16 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 49.26% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a 49.26% increase, with the full-year FY2024 number at $1.1 million, up 84.32% from a year prior.
  • Receivables was $1.0 million for Q3 2025 at International Stem Cell, down from $1.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.1 million in Q2 2025 to a low of $427000.0 in Q3 2022.
  • A 5-year average of $734210.5 and a median of $680000.0 in 2024 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 109.43% in 2021; the steepest drop was 61.6% in 2021.
  • International Stem Cell's Receivables stood at $844000.0 in 2021, then dropped by 11.49% to $747000.0 in 2022, then decreased by 23.16% to $574000.0 in 2023, then skyrocketed by 84.32% to $1.1 million in 2024, then fell by 4.06% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Receivables are $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $851000.0 (Q1 2025).